NRAS and hepatocellular carcinoma: These included the well-established NRAS activating mutation Q61L, which fully explains the constitutively elevated ERK phosphorylation and the insensitivity to the effects of the dominant negative H-Ras17N mutant that we observed in HepG2 hepatoma cells.